Malignancy in Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a multisystem inflammatory condition with an increasing number of new potential immunologic targets. These targets have shed light on both inflammatory and malignancy pathways given the interconnection between immunity and malignancy. In this review, we describe the various malignancies associated with SLE, as well as certain cellular pathways which contribute to dysregulated immunity in SLE and malignancy. This new appreciation for cancer risk in SLE adds yet another component to the management of SLE patients. Aside from managing the direct inflammatory consequences of SLE, part of a SLE patient’s treatment should also include consideration of cancer risk profiles and knowing what types of cancer screening should be advocated. While current evidence for cancer screening in SLE is limited, cancer screening in SLE and other autoimmune conditions will likely be a growing focus of interest.